99.5% PURITY
DUAL GIP / GLP-1 AGONIST
Tirzepatide
10 mg vial · lyophilized
Dual incretin receptor agonist combining GIP and GLP-1 activity. The most well-studied dual-incretin to date, with extensive Phase III data on glycemic control and weight recomposition.
Half-Life
~5 days (weekly dosing)
Storage
Lyophilized: 2–8 °C. Reconstituted: 2–8 °C, use within 30 days.
Dual incretin receptor agonist combining GIP and GLP-1 activity. The most well-studied dual-incretin to date, with extensive Phase III data on glycemic control and weight recomposition.
Who it's for
Researchers studying glycemic control, weight recomposition, and cardiometabolic markers.
Key things to know
- •Weekly subcutaneous dose, titrated every 4 weeks per published protocol.
- •Common research adjuncts: B-vitamin complex and electrolytes due to reduced food intake.
- •Slower gastric emptying is the dominant satiety mechanism.
- •Discontinuation typically follows a gradual taper to avoid metabolic rebound.
Research Highlights
- •SURMOUNT-1: ~20.9% mean weight reduction at highest dose over 72 weeks
- •SURPASS program demonstrated superior HbA1c reduction vs. semaglutide
